Bangladesh vs Cameroon: Average cost of drugs for extensively drug-resistant tuberculosis
Bangladesh
442 constant 2022 US$
in 2024
Cameroon
227 constant 2022 US$
in 2024
Bangladesh rank
51st
Cameroon rank
54th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Bangladesh
- Cameroon
How they compare
Bangladesh currently reports 442 constant 2022 US$ against 227 constant 2022 US$ in Cameroon, a difference of 215 constant 2022 US$.
That makes Bangladesh's figure about 1.9 times Cameroon's.
The two have swapped places 2 times across 8 shared years of data; in 2017 it was Bangladesh ahead.
Bangladesh ranks 51st and Cameroon ranks 54th of 56 countries.
Bangladesh has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Bangladesh | Cameroon | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 4,869 constant 2022 US$ | 4,251 constant 2022 US$ | 618 constant 2022 US$ | Bangladesh |
| 2020s | 3,292 constant 2022 US$ | 2,687 constant 2022 US$ | 605.4 constant 2022 US$ | Bangladesh |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Bangladesh or Cameroon?
- Bangladesh, at 442 constant 2022 US$ against 227 constant 2022 US$ in Cameroon as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Bangladesh and Cameroon?
- 215 constant 2022 US$, with Bangladesh ahead.
- How many years of comparable data are there for Bangladesh and Cameroon?
- 8 years are reported by both, from 2017 to 2024.
- How do Bangladesh and Cameroon rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Bangladesh ranks 51st and Cameroon ranks 54th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.